Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Pharmaceutical firm Eli Lilly invested $10m in US-based exosome drug developer Evox Therapeutics on Tuesday, supplying the capital through convertible bond financing alongside a $20m upfront payment as part of a research collaboration and licence deal. Evox had previously raised about $60m including $45.4m in a 2018 series B round led by Redmile Group and…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.